Literature DB >> 10398118

Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study.

C E Whittles1, L R Biddlestone, A Burton, H Barr, J A Jankowski, P J Warner, N A Shepherd.   

Abstract

The balance between proliferation and apoptosis within a tissue is important in controlling its overall growth. When either or both are altered, uncontrolled cell proliferation can contribute to cancer. The aim of this study was to investigate apoptosis and proliferation in the progression from Barrett's oesophagus to adenocarcinoma. Fifty-one paraffin sections of Barrett's mucosa with both intestinal and gastric-type Barrett's mucosa, dysplasia, and adenocarcinoma, from 28 patients, were examined for apoptosis using haematoxylin and eosin (H&E)-stained sections counterstained immunohistochemically with CD45 to distinguish leucocytes from apoptotic bodies. Proliferation was detected by immunohistochemistry using the MIB-1 (Ki-67) antibody. There was an increase in proliferation in dysplastic and carcinomatous tissue compared with metaplastic tissue (p=0.0001). In dysplasia, proliferation was distributed throughout the basal-luminal axis, whereas in metaplasia, cell division was compartmentalized to the lower crypt (p<0.001). Conversely, there was a decrease in apoptosis in the upper crypt and luminal surface in dysplasia and adenocarcinoma compared with metaplasia (p<0.0008). There was a significant increase in apoptotic activity in intestinal-type Barrett's mucosa compared with gastric-type. There was a highly significant increase in the glandular proliferation to apoptosis ratio (GPAR) in the progression of metaplasia to dysplasia to adenocarcinoma (p=0.001). The shift in the GPAR in the progression of neoplastic change suggests that it may be a useful and sensitive marker of neoplastic change in Barrett's oesophagus, especially if the assessment of both apoptotic and proliferative activity in the mucosa can be made easier by more sophisticated technical methods. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  1999        PMID: 10398118     DOI: 10.1002/(SICI)1096-9896(199904)187:5<535::AID-PATH302>3.0.CO;2-G

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  14 in total

1.  Barrett's oesophagus and proton pump inhibitors: a pathological perspective.

Authors:  N A Shepherd
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

Review 2.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

3.  Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus.

Authors:  Ewa E Hennig; Michal Mikula; Janina Orlowska; Dorota Jarosz; Andrzej Bielasik; Jaroslaw Regula; Jerzy Ostrowski
Journal:  J Mol Med (Berl)       Date:  2007-10-19       Impact factor: 4.599

4.  Defining Cancer Risk in Barrett's Esophagus: A Pathologist's Perspective.

Authors:  Amy E Noffsinger
Journal:  Gastrointest Cancer Res       Date:  2008-11

5.  Influence of acid and bile acid on ERK activity, PPARgamma expression and cell proliferation in normal human esophageal epithelial cells.

Authors:  Zhi-Ru Jiang; Jun Gong; Zhen-Ni Zhang; Zhe Qiao
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

6.  Proliferative activity in Barrett's esophagus before and after antireflux surgery.

Authors:  L Q Chen; C Y Hu; L Gaboury; M Pera; P Ferraro; A C Duranceau
Journal:  Ann Surg       Date:  2001-08       Impact factor: 12.969

7.  Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas.

Authors:  Howard C Crawford; Charles R Scoggins; M Kay Washington; Lynn M Matrisian; Steven D Leach
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

8.  Curcumin abrogates bile-induced NF-κB activity and DNA damage in vitro and suppresses NF-κB activity whilst promoting apoptosis in vivo, suggesting chemopreventative potential in Barrett's oesophagus.

Authors:  N Rawat; A Alhamdani; E McAdam; J Cronin; Z Eltahir; P Lewis; P Griffiths; J N Baxter; G J S Jenkins
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

Review 9.  Reflux esophagitis, high-grade neoplasia, and early Barrett's carcinoma-what is the place of the Merendino procedure?

Authors:  A H Hölscher; D Vallböhmer; C Gutschow; E Bollschweiler
Journal:  Langenbecks Arch Surg       Date:  2008-11-07       Impact factor: 3.445

Review 10.  Role of interleukin-6 in Barrett's esophagus pathogenesis.

Authors:  Katerina Dvorak; Bohuslav Dvorak
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.